{
  "docId": "019de074-461e-7658-adac-5d98e29da216",
  "docSlug": "6158bdf12351a4a226761fe3aa786b96",
  "documentTitle": "Alkermes | Results Presentation Deck | 24 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 24,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide outlines the strategic focus of the company following the spin-off of its oncology business.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-461e-7658-adac-5d98e29da216/20",
  "deckHref": "/decks/019de074-461e-7658-adac-5d98e29da216",
  "deckJsonHref": "/decks/019de074-461e-7658-adac-5d98e29da216.json",
  "deckAnchorHref": "/decks/019de074-461e-7658-adac-5d98e29da216#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "callout",
      "text": "Builds on Alkermes' innovation and excellence in neuroscience",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd3e5de1-a481-4a2b-96d7-c4072bb0fbeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Separation expected to enhance profitability",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb9d00f0-03f7-4e41-8474-0bef22be4079",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "*Assuming separation of the Company's oncology business is effected through a spin-off of the oncology business into an independent, publicly-traded company",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d806ae1d-0aed-45a0-b342-2ca8fe3f8286",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.66,
        "y": 0.3
      },
      "kind": "list",
      "text": "Development Pipeline: Early-stage neuroscience pipeline; ALKS 2680, orexin 2 receptor agonist in phase 1; Portfolio of preclinical neuroscience assets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dc1e133-6a98-4e8d-905d-8c5cd00d5a52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "list",
      "text": "Proprietary Products: Topline primarily driven by growth of proprietary commercial products in addiction and psychiatry; Complex manufacturing capabilities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab0c695f-1c1a-4818-bc33-7b986a34def5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.36,
        "y": 0.3
      },
      "kind": "list",
      "text": "Commercial Capabilities: Established commercial capabilities in complex psychiatry and addiction markets; Opportunity to capture further operating leverage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b75141b4-b648-49d5-9906-6571cb3fb3be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Post-Separation Alkermes* Pure-Play, Commercial-Stage Neuroscience Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bee37838-3455-47ad-9a29-dedd2d0a8f47",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 19,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "173eb554-351f-4bf0-a453-021007485622",
      "evidence": "Slide 19 emphasizes the company's priorities to unlock value in 2023",
      "position": 0,
      "objective": "Highlighting the importance of unlocking value in 2023",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}